METTL3

Across TCGA pan-cancer cohorts, METTL3 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of METTL3’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where METTL3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types METTL3 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

PDAC, LUAD, and LSCC are the cancer types where METTL3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	All	−0.177	<.001	9	view →
LUAD	Male	All	+0.117	<.001	6	view →
LSCC	Male	All	+0.095	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

METTL3–PDAC

Open the PDAC breakdown →